Clinical trial
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555
Study timeline
Study start (actual)2020-07-20Date precision: day
Registry last updated2026-07-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Recurrent Ependymomaunresolved
Recurrent Ewing Sarcomaunresolved
Recurrent Hepatoblastomaunresolved
Recurrent Langerhans Cell Histiocytosisunresolved
Recurrent Malignant Germ Cell Tumorunresolved
Recurrent Malignant Gliomaunresolved
Recurrent Malignant Solid Neoplasmunresolved
Recurrent Medulloblastomaunresolved
Recurrent Neuroblastomaunresolved
Recurrent Non-Hodgkin Lymphomaunresolved
Recurrent Osteosarcomaunresolved
Recurrent Rhabdoid Tumorunresolved
Recurrent Rhabdomyosarcomaunresolved
Recurrent Soft Tissue Sarcomaunresolved
Recurrent WHO Grade 2 Gliomaunresolved
Refractory Ependymomaunresolved
Refractory Ewing Sarcomaunresolved
Refractory Hepatoblastomaunresolved
Refractory Langerhans Cell Histiocytosisunresolved
Refractory Malignant Germ Cell Tumorunresolved
Refractory Malignant Gliomaunresolved
Refractory Malignant Solid Neoplasmunresolved
Refractory Medulloblastomaunresolved
Refractory Neuroblastomaunresolved
Refractory Non-Hodgkin Lymphomaunresolved
Refractory Osteosarcomaunresolved
Refractory Rhabdoid Tumorunresolved
Refractory Rhabdomyosarcomaunresolved
Refractory Soft Tissue Sarcomaunresolved
Refractory WHO Grade 2 Gliomaunresolved
Wilms Tumorunresolved
Interventions
IvosidenibDRUG · verified · RxNorm: ivosidenib
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Children's Oncology Groupcollaborator
Mapped research locations
New YorkNew York, United States4Las VegasNevada, United States4ChicagoIllinois, United States3Los AngelesCalifornia, United States3BaltimoreMaryland, United States3St LouisMissouri, United States3MiamiFlorida, United States3OrlandoFlorida, United States3HoustonTexas, United States2BostonMassachusetts, United States2PhiladelphiaPennsylvania, United States2DallasTexas, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04195555 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.